Alpha-particle carcinogenesis in Thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis.
We studied the alpha-radiation risks in patients who received injections of Thorotrast, an X-ray contrast medium used in Europe, Japan, and the United States from 1930 to 1955. Thorotrast was composed of thorium dioxide (ThO2) and Th-232, a naturally occurring radionuclide. Because the physical half-life of ThO2 is 14 billion years and Thorotrast is hardly eliminated from the body, tissues in which it was deposited are irradiated by alpha-radiation for the entire lifetime of the subject. The dosimetry of Thorotrast patients is very complicated, but currently its reliability is quite high compared with other irradiated populations. The major causes of the death of Thorotrast patients are liver cancer, liver cirrhosis, leukemia, and other cancers. Three histologies of liver cancer are found: cholangiocarcinoma, hepatocellular carcinoma, and angiosarcoma. Although cholangiocarcinoma is the most frequent, angiosarcoma is characteristic of alpha-radiation. Among blood neoplasms with a higher incidence of increase than the general population, erythroleukemia and myelodysplastic syndrome were remarkable. Thorotrast patients exhaled a high concentration of radon (Rn-220), a progeny of Th-232, but no excesses of lung cancer in the patients of Japan, Germany, and Denmark were reported. Mutation analyses of p53 genes and loss of heterozygosity (LOH) studies at 17p locus were performed to characterize the genetic changes in Thorotrast-induced liver tumors. Interestingly, LOH, supposedly corresponding to large deletions was not frequent; most mutations were transitions, also seen in tumors of the general population, suggesting that genetic changes of Thorotrast-induced cancers are mainly delayed mutations, and not the result of the direct effects of radiation.
Ishikawa
Y
Y
Department of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo.
Wada
I
I
Fukumoto
M
M
D000328:Adult; D000368:Aged; D000512:Alpha Particles / Q000009:adverse effects*; D002273:Carcinogens / Q000009:adverse effects* / Q000493:pharmacokinetics; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology*; D002423:Cause of Death; D018281:Cholangiocarcinoma / Q000453:epidemiology / Q000209:etiology*; D004249:DNA Damage; D004252:DNA Mutational Analysis; D016021:Epidemiologic Studies; D005060:Europe / Q000453:epidemiology; D005260:Female; D016158:Genes, p53; D006207:Half-Life; D006394:Hemangiosarcoma / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007938:Leukemia / Q000453:epidemiology / Q000209:etiology; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000209:etiology; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology*; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries; D018570:Risk Assessment; D013911:Thorium Dioxide / Q000009:adverse effects* / Q000493:pharmacokinetics; D014481:United States
D002273:Carcinogens; D013911:Thorium Dioxide